Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use IMULDOSA safely and effectively. See full prescribing information for IMULDOSA. IMULDOSA (ustekinumab-srlf) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 IMULDOSA (ustekinumab-srlf) is biosimilar* to STELARA ®(ustekinumab)
Medication labelWhy this: Advisory · dailymed-prescription
IMULDOSA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. IMULDOSA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. IMULDOSA is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease. IMULDOSA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
- generic_name
- ustekinumab-srlf
- product_names
- ustekinumab-srlf
- ndc
- 69448-018, 69448-018-63, 69448-017, 69448-017-63, 69448-019, 69448-019-26
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en